Neil M. Iyengar, MD

Articles

Considering Novel Therapy for HER2+ Metastatic Breast Cancer

April 29th 2022

A summary of sequencing therapy in the HER2+ metastatic breast cancer treatment paradigm followed by excitement for novel therapies under investigation.

Patient Profile 2: 3L Therapy for Triple-Positive mBC

April 29th 2022

Before closing out their discussion on the second patient profile, experts review third-line treatment selection for triple-positive metastatic breast cancer.

Patient Profile 2: Second-Line Therapy for Triple-Positive mBC

April 22nd 2022

Expert perspectives on second-line treatment options available for patients who progress with triple-positive metastatic breast cancer.

Patient Profile 2: Patient with Triple-Positive mBC

April 22nd 2022

Experts discuss the use of frontline therapy in patients with triple-positive metastatic breast cancer.

Patient Profile 1: Sequencing Therapies in HER2+ mBC

April 15th 2022

Shared insights on the use of therapies as a patient progresses with HER2+ metastatic breast cancer, which includes sequencing through T-DM1 [trastuzumab emtansine], tucatinib/capecitabine/trastuzumab, and trastuzumab deruxtecan.

Patient Profile 1: Second-Line Therapy for HER2+ mBC

April 15th 2022

Expert perspectives on the selection of second-line therapy when patients progress with HER2+ metastatic breast cancer.

Patient Profile 1: Frontline Therapy for HER2+ mBC

April 8th 2022

Centering discussion on a patient profile of HER2+ metastatic breast cancer, experts elucidate frontline therapy selection in this setting.

Recent Trial Data in HER2+ Metastatic Breast Cancer

April 8th 2022

Before moving on to the patient profiles, expert panelists review recent clinical trial data that have impacted treatment selection and sequencing in HER2+ metastatic breast cancer.

Selecting and Sequencing Therapy for HER2+ Breast Cancer

April 1st 2022

Shared insight on the optimal sequencing of therapeutic agents for patients undergoing treatment for HER2+ metastatic breast cancer.

HER2+ Breast Cancer: Overview of the Treatment Armamentarium

April 1st 2022

Comprehensive insight on therapeutic classes and agents approved in the setting of HER2+ metastatic breast cancer, with a specific focus on how these therapies fit into current treatment strategies.

Dr. Iyengar on Trastuzumab Deruxtecan in HER2-Low Breast Cancer

February 21st 2022

Neil M. Iyengar, MD, discusses the use of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.

Treatment Advances in HR+/HER2- MBC

November 29th 2021

Final takeaways from a discussion on best practices treating HR+/HER2- metastatic breast cancer with CDK4/6 inhibitors and PI3K therapies based on data presented at ESMO 2021.

Sequencing Therapy in HR+/HER2- MBC

November 29th 2021

Variables that impact how breast oncologists should sequence therapies when managing patients with HR+/HER2- metastatic breast cancer.

PI3K Therapy for HR+/HER2- MBC: Metabolic Syndrome

November 22nd 2021

Strategies to help breast oncologists counsel patients on metabolic conditions when treating patients with HR+/HER2- metastatic breast cancer with PI3K inhibitors.

Managing Patients With HR+ MBC on PI3K Therapy

November 22nd 2021

Breast oncologists share pearls regarding best practices treating patients with HR+/HER2- metastatic breast cancer with PI3K inhibitor therapy and mitigating treatment-related adverse events.

PI3K Inhibitors for PIK3CA-Mutated HR+ MBC

November 15th 2021

Considerations for treating patients with HR+/HER2- metastatic breast cancer with alpelisib, a PI3K inhibitor, following frontline treatment with a CDK4/6 inhibitor.

CDK4/6 Treatment Selection for HR+/HER2- MBC

November 8th 2021

The impact of recent data presented at ESMO 2021 in terms of selecting an appropriate CDK4/6 inhibitor as first-line treatment of HR+/HER2- metastatic breast cancer.

Comparison of CDK4/6 Therapies for HR+/HER2- MBC

November 8th 2021

Similarities and differences between available CDK4/6 inhibitors used to treat HR+/HER2- metastatic breast cancer.

HR+/HER2- MBC: CKD4/6 Inhibitor Treatment Toxicities

November 1st 2021

Clinical pearls regarding best practices preventing and/or managing common treatment-related adverse events associated with CDK4/6 inhibitors used to treat HR+/HER2- metastatic breast cancer.

MONALEESA Data in HR+/HER2- MBC: Sequencing Therapy

October 25th 2021

Insight on how to best sequence therapy for patients with HR+/HER2- advanced breast cancer based on updated data from the MONALEESA trials.